object
evalu
use
aspergillu
fumigatu
quantit
pcr
assay
perform
bronchoalveolar
lavag
fluid
bal
diagnosi
prognosi
invas
noninvas
aspergillosi
method
retrospect
studi
involv
atrisk
patient
either
hematolog
disord
immunosuppress
condit
notabl
solid
organ
transplant
thirtyf
patient
provenprob
aspergillosi
thirteen
chronic
noninvas
aspergillosi
compar
pcr
galactomannan
index
mycolog
analysi
bal
result
invas
aspergillosi
ia
pcr
perform
bal
yield
sensit
specif
compar
galactomannan
index
mycolog
examin
yield
sensit
specif
respect
consid
chronic
aspergillosi
case
pcr
galactomannan
index
mycolog
examin
yield
sensit
specif
respect
fungal
load
bal
evalu
pcr
abl
discrimin
aspergillosi
contamin
invas
noninvas
form
final
fungal
load
predict
mortal
mortal
patient
less
copiesml
versu
patient
cutoff
p
result
indic
aspergillu
pcr
bal
particular
interest
diagnosi
prognosi
ia
likewis
interest
tool
diagnosi
noninvas
form
invas
aspergillosi
ia
particularli
sever
diseas
immunocompromis
patient
diagnosi
remain
difficult
often
base
bodi
argument
built
around
host
clinic
radiolog
mycolog
criteria
defin
jointli
european
organis
research
treatment
cancer
nation
institut
allergi
infecti
diseas
mycos
studi
group
eortcmsg
de
pauw
et
al
although
includ
criteria
detect
aspergillu
dna
blood
sampl
realtim
polymeras
chain
reaction
pcr
long
histori
use
shown
interest
test
diagnos
ia
neutropen
nonneutropen
patient
suarez
et
al
imbert
et
al
moreov
approach
shown
predict
abil
diseas
outcom
imbert
et
al
consensu
among
expert
inclus
eortcmsg
criteria
white
et
al
patterson
et
al
ullmann
et
al
even
less
sampl
invas
respiratori
sampl
bronchoalveolar
lavag
bal
fluid
may
use
ia
diagnosi
eortcmsg
recommend
use
galactomannan
bal
mycolog
criterion
de
pauw
et
al
even
studi
show
heterogen
perform
optim
cutoff
valu
definit
determin
zou
et
al
aspergillu
pcr
also
practic
bal
sampl
studi
show
promis
perform
howev
less
known
concern
potenti
use
tuon
zou
et
al
grancini
et
al
guegan
et
al
otherwis
noninvas
aspergillosi
occur
nonimmunocompromis
patient
compris
sever
clinic
form
variabl
sever
includ
chronic
pulmonari
aspergillosi
cpa
allerg
diseas
allerg
bronchopulmonari
aspergillosi
abpa
kosmidi
den
ia
diagnosi
difficult
reli
mainli
clinic
radiolog
find
associ
evid
aspergillu
respiratori
sampl
posit
antiaspergillu
antibodi
serum
guidelin
edit
jointli
european
societi
clinic
microbiolog
infecti
diseas
european
respiratori
societi
escmid
recommend
use
aspergillu
pcr
bal
diagnosi
noninvas
aspergillosi
cii
grade
thu
present
studi
evalu
inhous
fumigatu
realtim
pcr
assay
comparison
galactomannan
gm
assay
mycolog
examin
diagnosi
invas
noninvas
form
aspergillosi
atrisk
patient
also
assess
contribut
pcr
prognosi
retrospect
singlecent
analysi
perform
februari
februari
la
hospit
tertiari
care
center
pari
franc
patient
least
aspergillu
pcr
perform
bal
due
risk
ia
suspicion
noninvas
form
aspergillosi
includ
studi
result
bal
mycolog
analysi
direct
examin
cultur
gm
serum
bal
pcr
serum
bal
obtain
routin
clinic
practic
accord
clinician
prescript
sampl
time
analys
perform
store
sampl
clinic
radiolog
data
collect
retrospect
thereaft
exclud
analys
patient
data
lack
studi
analyz
result
obtain
routin
clinic
practic
specif
author
research
ethic
committe
requir
present
studi
focus
patient
provenprob
ia
accord
extend
eortcmsg
criteria
de
pauw
et
al
noninvas
aspergillosi
possibl
ia
case
exclud
studi
bal
posit
cultur
aspergillu
sp
posit
gm
index
serum
index
posit
pcr
serum
use
mycolog
criteria
probabl
case
risk
factor
known
lead
invas
aspergillosi
liver
cirrhosi
sever
acut
respiratori
distress
syndrom
extracorpor
membran
oxygen
termin
chronic
obstruct
pulmonari
diseas
termin
solid
malign
ad
host
factor
avoid
inclus
bia
gm
pcr
result
bal
exclud
mycolog
criteria
diagnosi
noninvas
form
made
patient
compat
clinic
radiolog
find
present
associ
posit
aspergillu
cultur
bal
presenc
seric
antiaspergillu
antibodi
serum
assess
realtim
pcr
assay
target
segment
ribosom
rna
code
dna
use
previous
describ
challier
et
al
suarez
et
al
imbert
et
al
dna
extract
perform
ml
bal
magna
pure
compact
larg
volum
kit
magna
pure
devic
roch
elut
volum
amplif
perform
fast
realtim
pcr
system
appli
biosystem
quantif
achiev
use
five
serial
dilut
plasmid
pgemt
contain
target
final
pcr
result
express
number
copi
per
ml
sampl
intern
control
use
assay
well
taqman
exogen
intern
posit
control
extract
control
albumin
gene
sampl
pcr
perform
duplic
singl
posit
well
consid
posit
result
gm
index
determin
enzym
immunoassay
biorad
accord
manufactur
recommend
result
consid
posit
two
determin
perform
two
differ
assay
sampl
show
index
equal
greater
serum
index
equal
greater
bal
test
perform
use
graphpad
prism
free
onlin
site
biostatgv
categor
variabl
compar
use
chi
test
fischer
exact
test
fungal
load
compar
use
student
ttest
surviv
distribut
use
logrank
test
pvalu
less
consid
statist
signific
studi
period
fumigatu
pcr
perform
patient
figur
clinic
data
avail
patient
bal
sampl
diagnos
proven
probabl
ia
made
respect
patient
accord
extend
eortcmsg
criteria
includ
serum
pcr
mycolog
criterion
mycolog
criterion
patient
two
probabl
case
involv
lung
one
digest
aspergillosi
mani
cultureposit
sampl
unknown
origin
posit
gm
pcr
result
serum
normal
full
thorac
ctscan
noninvas
form
aspergillosi
diagnos
patient
overal
invas
chronic
aspergillosi
incid
respect
studi
period
http
among
patient
provenprob
invas
aspergillosi
femal
male
tabl
median
age
year
rang
sixteen
patient
receiv
corticoid
therapi
ten
patient
neutropen
absolut
neutrophil
count
time
diagnosi
underli
condit
mainli
solid
organ
transplant
n
heart
liver
kidney
liverkidney
haematopoiet
stem
cell
transplant
n
hematolog
malign
n
other
risk
factor
present
patient
sever
acut
respiratori
distress
syndrom
ecmo
n
oncolog
diseas
n
alcohol
liver
cirrhosi
n
cardiogen
shock
ecmo
n
termin
chronic
obstruct
bronchopneumonia
n
overal
mortal
invas
aspergillosi
among
patient
noninvas
aspergillosi
clinic
form
cpa
patient
includ
chronic
cavitari
pulmonari
aspergillosi
n
aspergilloma
n
chronic
necrotis
pulmonari
aspergillosi
n
one
patient
sinu
aspergilloma
patient
aspergillu
bronchiti
last
one
allerg
bronchopulmonari
aspergillosi
threemonth
mortal
rate
significantli
lower
invas
form
p
fisher
exact
test
tabl
therefor
pcr
provid
significantli
better
sensit
gm
index
p
mycolog
examin
p
note
gm
serum
posit
index
ia
patient
sensit
exclud
patient
serum
pcr
mycolog
criterion
lead
result
sensit
bal
pcr
bal
gm
index
bal
mycolog
examin
ci
ci
ci
respect
specif
pcr
gm
index
mycolog
examin
ci
ci
ci
respect
note
decreas
gm
index
posit
cutoff
led
increas
sensit
ci
still
lower
pcr
p
decreas
specif
ci
howev
half
bal
gm
index
compris
fals
posit
one
four
pcrneg
invas
case
caus
nidulan
speci
detect
pcr
use
studi
two
other
show
pulmonari
involv
therefor
sensit
pcr
pulmonari
form
fumigatu
ia
seri
ad
either
mycolog
examin
gm
determin
pcr
slightli
improv
sensit
especi
nona
fumigatu
ia
combin
three
method
pcr
posit
test
bal
ia
patient
wherea
never
case
gm
mycolog
examin
therefor
exclud
pcr
combin
led
decreas
sensit
figur
statist
signific
differ
observ
neutropen
nonneutropen
patient
group
patient
provenprob
ia
sensit
pcr
gm
index
mycolog
examin
n
n
neutropen
patient
n
n
nonneutropen
patient
respect
data
shown
specif
n
n
neutropen
patient
n
n
nonneutropen
patient
respect
pcr
gm
index
mycolog
examin
posit
respect
case
noninvas
chronic
aspergillosi
therefor
sensit
pcr
ci
consider
superior
gm
index
ci
p
similar
mycolog
examin
ci
posit
predict
valu
ppv
form
aspergillosi
ci
ci
ci
pcr
gm
mycolog
examin
respect
howev
consid
tool
diagnosi
ia
lead
decreas
ppv
tabl
inde
invas
form
pcr
yield
ppv
ci
neg
predict
valu
npv
ci
among
patient
ia
patient
free
antifung
therapi
time
bal
sampl
other
patient
receiv
antifung
treatment
patient
receiv
voriconazol
receiv
liposom
amphotericin
b
receiv
voriconazol
plu
liposom
amphotericin
b
patient
caspofungin
patient
given
posaconazol
averag
durat
moldact
drug
sampl
day
day
gm
valu
bal
avail
patient
show
differ
nontreat
group
patient
receiv
antifung
drug
bal
sampl
mean
valu
versu
respect
p
mann
whitney
test
pcr
sensit
method
posit
nonaspergillosi
condit
due
either
contamin
sampl
airborn
conidia
presenc
fortuit
nonspecif
pathogen
aspergillu
airway
moreov
realtim
pcr
quantifi
fungal
load
result
express
number
aspergillu
gene
copi
per
ml
bal
consid
assess
abil
fungal
load
predict
clinic
form
aspergillosi
distinguish
invas
noninvas
nonaspergillosi
diseas
analysi
pcrposit
bal
number
copi
express
show
latter
significantli
higher
bal
sampl
patient
aspergillosi
comparison
bal
sampl
patient
nonaspergillosi
condit
p
ttest
figur
howev
number
copi
statist
differ
p
ttest
invas
chronic
form
although
relat
statist
significantli
higher
fungal
load
comparison
nonaspergillosi
pcrposit
group
figur
result
suggest
fungal
load
might
use
discrimin
aspergillosi
contaminationclin
irrelev
colon
figur
fungal
load
assess
aspergillu
pcr
bronchoalveolar
lavag
fluid
discrimin
aspergillosi
contaminationclin
irrelev
colon
patient
aspergillosi
higher
aspergillu
pcr
copi
number
compar
patient
aspergillosi
exclud
p
ttest
b
patient
either
invas
chronic
form
aspergillosi
higher
aspergillu
copi
number
compar
patient
aspergillosi
exclud
howev
signific
differ
identifi
patient
invas
chronic
form
aspergillosi
p
ttest
p
ttest
error
bar
repres
mean
standard
deviat
furthermor
fungal
load
bal
predictor
mortal
invas
pulmonari
aspergillosi
analyz
analysi
three
pcrneg
invas
case
one
due
nidulan
detect
employ
pcr
techniqu
two
lung
involv
exclud
roc
curv
indic
cutoff
copiesml
optim
threshold
supplementari
figur
patient
pcr
result
strictli
copiesml
significantli
higher
probabl
surviv
day
diagnosi
n
surviv
compar
pcr
result
cutoff
n
surviv
median
surviv
day
p
logrank
test
figur
test
hazard
ratio
ci
ratio
characterist
patient
ie
age
sex
ratio
underli
diseas
antifung
therapi
well
interv
sampl
start
target
antifung
therapi
differ
two
group
tabl
consid
invas
case
studi
due
fumigatu
even
nonpulmonari
form
found
less
statist
signific
result
p
data
shown
interestingli
gm
index
bal
supernat
also
permit
kind
discrimin
index
cutoff
provid
numer
falseneg
test
includ
analysi
figur
patient
gm
indic
significantli
higher
probabl
surviv
day
diagnosi
n
surviv
compar
result
cutoff
n
surviv
median
surviv
day
p
logrank
test
test
hazard
ratio
ci
ratio
aspergillu
dna
detect
diagnosi
aspergillosi
subject
studi
year
yamakami
et
al
numer
author
demonstr
sensit
rang
specif
state
aspergillu
pcr
blood
interest
tool
diagnosi
invas
aspergillosi
atrisk
patient
mengoli
et
al
arvan
et
al
arvan
et
al
imbert
et
al
nonetheless
moment
expert
consensu
recommend
use
certain
precaut
opinion
still
diverg
patterson
et
al
furthermor
note
literatur
perform
aspergillu
pcr
assess
blood
sampl
much
frequent
respiratori
sampl
bal
sputum
literatur
essenti
focus
patient
hematolog
condit
sun
et
al
torelli
et
al
hoenigl
et
al
boch
et
al
includ
popul
luong
et
al
guegan
et
al
present
work
indic
pcr
perform
bal
particular
interest
diagnosi
invas
aspergillosi
provid
sensit
specif
valu
similar
report
previou
report
show
sensibl
rang
specif
tuon
luong
et
al
grancini
et
al
guegan
et
al
particularli
rate
sensit
observ
pcr
bal
superior
observ
gm
index
whatev
cutoff
use
mycolog
cultur
alreadi
demonstr
mycolog
cultur
contradict
previou
report
gm
show
higher
sensit
pcr
guegan
et
al
also
underlin
sensit
analysi
limit
case
invas
aspergillosi
pulmonari
involv
fumigatu
caus
speci
last
pulmonari
case
diagnos
clinic
radiolog
evid
posit
gm
pcr
serum
cultur
alway
perform
enabl
isol
fungu
ie
yeast
mold
retriev
strain
also
permit
evalu
suscept
fungu
antifung
drug
via
determin
minim
inhibitori
concentr
gm
determin
strongli
recommend
diagnosi
screen
patient
hematolog
condit
condit
solid
organ
transplant
recipi
patterson
et
al
contrast
work
indic
pcr
interest
hematolog
nonhematolog
patient
includ
solid
organ
transplant
recipi
account
third
concern
popul
demonstr
use
intens
care
unit
patient
diagnosi
ia
remain
difficult
need
improv
previous
report
guegan
et
al
high
sensit
pcr
also
use
diagnosi
chronic
aspergillosi
form
npv
interest
whatev
form
posit
pcr
respiratori
sampl
may
due
invas
aspergillosi
chronic
aspergillosi
clinic
irrelev
situat
ie
contamin
fortuit
colon
interestingli
found
fungal
load
distinguish
aspergillosi
nonaspergillosi
patholog
thu
may
use
discrimin
infect
colon
howev
studi
contradict
previou
work
luong
et
al
grancini
et
al
fungal
load
abl
distinguish
invas
noninvas
form
find
particularli
surpris
invas
chronic
patholog
may
involv
high
fungal
burden
although
particular
interest
diagnosi
aspergillosi
bronchoalveolar
lavag
endoscop
procedur
thu
obtain
sampl
may
difficult
fragil
patient
note
proport
patient
hematolog
condit
patient
neutropen
smaller
studi
previou
work
pcr
serum
work
also
report
initi
fungal
load
determin
pcr
serum
highli
predict
mortal
imbert
et
al
therefor
although
bal
physiolog
sampl
subject
procedur
variat
affect
dilut
investig
whether
aspergillu
dna
quantif
bal
could
use
predict
outcom
invas
diseas
focus
invas
pulmonari
aspergillosi
found
pcr
threshold
copiesml
could
discrimin
patient
low
threshold
high
probabl
mortal
note
gm
index
also
discrimin
two
group
analysi
includ
numer
fals
neg
ie
cutoff
suggest
gm
may
better
suit
predict
outcom
rather
diagnosi
nonetheless
sever
limit
studi
first
reliabl
gold
standard
diagnosi
ia
major
case
probabl
ia
evalu
diagnosi
perform
test
may
includ
bia
avoid
inclus
bia
test
want
evalu
ie
gm
pcr
bal
exclud
diagnosi
criteria
secondli
pcr
use
specif
fumigatu
speci
thu
amplifi
genom
import
speci
flavu
niger
howev
look
case
invas
aspergillosi
posit
cultureand
therefor
identif
speci
levelther
one
case
nonfumigatu
nidulan
diagnos
seri
echo
find
one
previou
studi
imbert
et
al
furthermor
even
commerci
multiplex
approach
lack
relev
speci
nidulan
chong
et
al
last
limit
method
design
detect
antifung
drug
resist
particularli
azol
resist
howev
involv
treatment
rather
diagnosi
latter
remain
main
purpos
aspergillu
pcr
techniqu
could
improv
ad
genetarget
pcr
buil
et
al
aspergillu
dna
detect
bronchoalveolar
lavag
fluid
pcr
interest
tool
diagnosi
invas
aspergillosi
sensit
far
better
gm
index
mycolog
examin
pcr
perform
bal
also
particular
interest
diagnosi
noninvas
aspergillosi
also
offer
high
neg
predict
valu
form
aspergillosi
howev
pcr
method
employ
studi
design
detect
nonfumigatu
speci
effort
necessari
overcom
limit
moreov
pcr
permit
quantif
fungal
load
posit
case
might
use
discrimin
aspergillosi
contamin
clinic
irrelev
colon
result
studi
also
indic
case
invas
pulmonari
aspergillosi
threshold
copiesml
use
discrimin
patient
low
threshold
high
probabl
mortal
cutoff
might
use
one
hand
identifi
patient
need
particularli
intens
care
design
clinic
studi
si
perform
data
analysi
particip
write
manuscript
im
mp
jyb
ft
fg
perform
experi
mu
vtd
particip
scientif
discuss
particip
write
manuscript
af
design
studi
perform
data
analysi
wrote
paper
author
contribut
manuscript
revis
read
approv
submit
version
work
support
intern
fund
